MARKET

IMNN

IMNN

Imunon Inc
NASDAQ
0.9031
-0.0421
-4.45%
Opening 11:39 12/04 EST
OPEN
0.9300
PREV CLOSE
0.9452
HIGH
0.9300
LOW
0.9020
VOLUME
13.82K
TURNOVER
0
52 WEEK HIGH
1.720
52 WEEK LOW
0.8448
MARKET CAP
8.49M
P/E (TTM)
-0.2845
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IMNN last week (1127-1201)?
Weekly Report · 5h ago
Weekly Report: what happened at IMNN last week (1120-1124)?
Weekly Report · 11/27 11:09
Weekly Report: what happened at IMNN last week (1113-1117)?
Weekly Report · 11/20 11:07
Positive Interim OVATION 2 Data Bolsters Confidence in Imunon Stock: An Analysis of Emily Bodnar’s Buy Rating
TipRanks · 11/14 17:35
Imunon Inc: Current report
Press release · 11/14 15:43
Imunon Inc: Quarterly report
Press release · 11/14 15:43
Earnings Scheduled For November 14, 2023
Curevac is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million. Caledonia mining is expected to report earnings for its third quarter. Curevac and other companies are expected to be reported before the bell.
Benzinga · 11/14 13:23
Imunon: Q3 Earnings Insights
Imunon reports its q3 earnings on november 14. Imunon beat estimates by 43.94%. Revenue was down $125 thousand from the same period last year. Last quarter the company beat on eps by $0.09 and the share price dropped 4.13%.
Benzinga · 11/14 13:15
More
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company. It is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. It has two platform technologies: TheraPlas platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and the PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 works by instructing the body to produce cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, it is conducting preclinical studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus to validate its PLACCINE platform. Its platform technologies are based on the delivery of nucleic acids with synthetic delivery systems that are independent of viral vectors or devices.

Webull offers Imunon Inc stock information, including NASDAQ: IMNN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMNN stock methods without spending real money on the virtual paper trading platform.